Cancer is constantly evolving. And so are we. It is for this reason that we are constantly seeking breakthrough therapies. We are focused exclusively on the development of new, innovative cancer medicines, that address unmet clinical need. That’s any cancer, through any mechanism, with any molecule. Find out more about how we do this through acquisition, development, and out-licensing: https://lnkd.in/eZdDtqz2
Ellipses Pharma
Biotechnology
London, England 2,851 followers
Ellipses Pharma is focused exclusively on the development of innovative cancer medicines and treatments.
About us
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments. Clinical trials are the route to developing more cancer treatments. All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients. We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective - making more treatments available to patients. Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel. Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.
- Website
-
http://www.ellipses.life
External link for Ellipses Pharma
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- London, England
- Type
- Privately Held
Locations
-
Primary
10 Stratton Street
London, England W1J 8LG, GB
Employees at Ellipses Pharma
Updates
-
Dr. Matthew Krebs highlights the importance of targeting resistance mechanisms & CNS activity in the treatment of RET+ NSCLC and how EP0031 represents a step forward in addressing these challenges. Watch the full interview here: https://lnkd.in/eK8ZJjYg #CancerResearch #Innovation
-
300 Voices, One Mission: Uniting global experts to accelerate cancer therapies together. Ellipses Pharma employs a unique, disruptive approach to drug development, supported by our Scientific Affairs Group (SAG) – the world's largest group of oncology key opinion leaders. Together, we de-risk asset selection and enhance success rates by aligning patient needs with cutting-edge science. Learn how our SAG is shaping the future of cancer therapies through collaborative insights and patient-centered strategies: https://lnkd.in/ezDnfYjb #EllipsesPharma #ScientificAdvisoryGroup #OncologyInnovation #DrugDevelopment
-
Spotlight on Our Scientific Affairs Group (SAG) Members: In our ongoing series highlighting the remarkable members of Ellipses Pharma's Scientific Affairs Group (SAG), we are pleased to feature Emiliano Calvo Aller. With a career dedicated to advancing clinical oncology and drug development, Professor Calvo's expertise and leadership are instrumental in shaping the future of cancer treatment. As Director of Clinical Research at START Madrid and President of the Intheos Foundation, Professor Calvo's influence spans international collaborations in early-phase clinical drug development and immunotherapy. His extensive contributions include directing the Oncology PhD Program at Universidad CEU San Pablo and serving on prestigious committees like ESMO - European Society for Medical Oncology and American Society of Clinical Oncology (ASCO), where he shapes clinical trial methodologies and therapeutic advancements. Joining the Ellipses SAG has empowered Professor Calvo to contribute his insights and expertise to evaluating and advancing innovative cancer medicines. His role enhances our ability to translate cutting-edge research into clinical practice, accelerating our mission to redefine cancer care. Keep following us as we meet more of our Scientific Affairs Group contributors at Ellipses Pharma.
-
-
Spotlight on Our Scientific Affairs Group (SAG) Members: Continuing our series showcasing the esteemed members of our Scientific Affairs Group (SAG) at Ellipses Pharma, we turn our focus to Professor Patrick Schöffski. With a distinguished career spanning medical oncology and experimental oncology research, as well as nearly 350 publications to his name, Professor Schöffski brings unparalleled expertise to our team. As Head of the Department of Medical Oncology at University Hospitals Leuven UZ Leuven and leader of the Laboratory of Experimental Oncology at KU Leuven, Professor Schöffski's contributions to cancer research are profound. His role as the former Secretary-General of EORTC and memberships in American Society of Clinical Oncology (ASCO) and American Association for Cancer Research highlight his influence in shaping clinical guidelines and advancing treatments for rare cancers. At Ellipses Pharma, Professor Schöffski's involvement in our SAG ensures rigorous evaluation and validation of experimental cancer therapies. His approach combines deep clinical insights with scientific rigor, setting high standards in precision medicine that align perfectly with our commitment to innovating cancer care. Stay tuned as we continue to spotlight exceptional individuals like Professor Patrick Schöffski, driving innovation and progress in oncology through our ongoing Scientific Affairs Group series at Ellipses Pharma.
-
-
Introducing Our Scientific Affairs Group (SAG) Members At Ellipses Pharma, we are privileged to work alongside some of the brightest minds in oncology. Today, we shine a spotlight on the members of our Scientific Affairs Group (SAG). These dedicated experts play a pivotal role in shaping the future of cancer treatment through their invaluable insights and contributions. Professor Giuseppe Curigliano, MD, PhD, exemplifies the caliber of expertise within our SAG. Professor Curigliano serves as the director of the Early Drug Development Division and holds the co-chair for the Experimental Therapeutics Program at the European Institute of Oncology in Milan, Italy. With a distinguished background in preclinical and translational research, Professor Curigliano's expertise spans across various prestigious institutions, including the Columbia University Comprehensive Cancer Center in New York, USA, and the Dana Farber Cancer Institute, Harvard Medical School in Boston, USA. As a recognized leader in the field, Professor Curigliano has significantly contributed to the advancement of oncology through his extensive involvement in guideline development, clinical trials, and translational research. His pioneering work in biomarker discovery, personalized therapies, and implementation of personalized medicine has garnered international acclaim and recognition. We are honored to have Professor Giuseppe Curigliano as a valued member of our Scientific Affairs Group, and we look forward to sharing more insights from our esteemed panel of experts as part of this series. Stay tuned as we continue to spotlight the exceptional individuals driving innovation and progress in oncology. #SAGSpotlight #OncologyExperts #EllipsesPharma
-
-
🚀 Exciting news from Ellipses Pharma! Our Scientific Affairs Group (SAG) has grown to over 300 expert advisors, from around the globe, making it the largest panel of key opinion leaders in oncology. This exceptional team of experts is crucial in validating the science and clinical application of our assets, helping us deliver groundbreaking solutions in oncology at a rapid pace. Their collective insights, obtained through our double blinded review process ensures an unbiased and independent appraisal of clinical data, driving our commitment to innovation and helping us to develop better medicines for patients. Discover how our SAG operates and why it’s a unique asset in our pursuit of excellence in oncology: https://lnkd.in/ezDnfYjb #Oncology #Innovation #EllipsesPharma #ScientificExcellence #KeyOpinionLeaders
-
As #ASCO24 comes to a close, we're reflecting on the incredible collaboration and dedication of the global oncology community. Together, we're advancing towards better treatments and outcomes for cancer patients worldwide. The research presented at #ASCO24 fills us with hope and promise for the future of cancer care. We extend our heartfelt gratitude to the entire Ellipses Pharma team for their tireless efforts in driving innovation and progress in oncology. Their dedication to developing transformative treatments like EP0031/A400 for RET-altered tumors is truly inspiring. As we leave #ASCO24, we remain committed to our mission of improving the lives of cancer patients through groundbreaking research and development. Thank you to everyone who contributed to making #ASCO24 a success. We look forward to continuing our journey together towards a world where cancer is no longer a threat. View our full portfolio: https://lnkd.in/e5EUrWbS #ASCO24 #CancerResearch
-
Dr. Elena Garralda Cabanas highlights the latest clinical data on EP0031/A400, at #ASCO24 our potential treatment for RET-altered tumors. To read more on the promising efficacy of EP0031 in NSCLC, thyroid, and other solid tumors, including durable responses in patients with brain metastases, please visit our website: https://lnkd.in/euyE8KF6 Stay tuned for more updates from the conference. #ASCO2024 #EllipsesPharma #EP0031 #CancerResearch
-
Today Dr Elena Garralda Cabanas has presented our phase 1 study data for EP0031 at #ASCO24 sharing more about this exciting asset for the potential treatment of RET-altered tumours.
-